CONSTELLATION TECHNOLOGIES LIMITED — Capital/Financing Update 2007

Aug 5, 2007

==> picture [91 x 72] intentionally omitted <==

6 August 2007

AGENIX COMPLETES $6.7M PLACEMENT OF SHARES TO FUND PROMISING DRUG DEVELOPMENT OPPORTUNITIES IN CHINA

Agenix announces the successful placement to institutional and sophisticated investors in Australia and Asia of 41,875,000 shares at $0.16 per share to raise $6,700,000 before costs, to assist with the funding of the Agenix Biopharmaceutical (Shanghai) drug development pipeline and to provide additional working capital.

Agenix had received approval from shareholders at its General Meeting on 17 April, 2007 to raise additional capital for that purpose by issuing up to 100 million new securities. ASX has granted Agenix a waiver from the 3 month period to issue those securities on the basis that the issue is completed on or before 16 August 2007.

Update on Agenix Biopharmaceutical (Shanghai) activities

1. YouHeDing

The company’s hepatitis B virus (HBV) drug, YouHeDing, has passed all regulatory clinical trial and manufacturing reviews by the State Food & Drug Administration of the People’s Republic of China (“SFDA”) and is awaiting market launch approval from SFDA.

We expect to receive that market launch approval and to be deriving revenue from drug sales in the People’s Republic of China during this half of the 2007 calendar year. Additional sales and marketing staff are in the process of being recruited preparatory to market launch approval.

At the company’s GMP manufacturing facility in Pudong, work-in-progress material has been manufactured through the 4[th] step of the manufacturing process, awaiting market launch approval before completing the 5[th] and final manufacturing step.

2. Additional potential revenue earning products

As a result of the SHRG acquisition, Agenix also acquired ownership of the following products:

• Haobai Shangshi Spray – pain relief induced by sprain, contusion and rheumatism;

• Compound Fluorouracil Oral Solution – supplemental treatment of digestive tract disease;

• Mannatide Oral Solution – supplemental treatment of hypoimmunity and side-effects induced by cancer therapy, including radiotherapy and chemotherapy;

• Huangdan Yinchen Keli – treatment of acute and chronic jaundice; and

• Yimucao Keli – pain relief.

3. Additional potential revenue to that forecast from sales of

YouHeDing

The above additional products are undergoing recertification with the SFDA for reentry to the market. Market launch of all products is expected in the current half of calendar year 2007. Annual revenue from these products during the 12 months after market launch of these products is expected to be around RMB10 million (A$1.550 million).

4. SHRG anti-viral product development pipeline

SHRG has a number of additional products in various early stages of development, including:

• Anti-colon cancer compound shows promising pre-clinical results

A compound developed by SHRG in association with No.2 Medical Military University in Shanghai has shown a tumour suppression rate higher than that of the control agent (a chemotherapeutic agent used in the treatment of colorectal and breast cancer) in pre-clinical trials in over 100 mice.

The compound also demonstrated potential efficacy against lung cancer, breast cancer and liver cancer in mice.

Planning is now underway to carry out further pre-clinical work before commencing a Phase I trial of the efficacy of the compound against colon cancer in humans toward the end of calendar year 2008.

• Anti-hepatitis B virus drug

A novel nucleoside anti-HBV agent has been developed by SHRG in association with No.2 Medical Military University which has shown promising suppression potential against HBV in pre-clinical trails in over 100 mice.

This agent is expected to enter a Phase I clinical trial in humans in 2008.

• Anti-viral drug shows efficacy against HIV and HBV

A novel anti-viral compound developed by SHRG in association with No. 2 Medical Military University has shown promising suppression potential against HBV in a small number (less than 10) ducks. Higher doses of the compound have shown promising suppression potential against HIV.

Further pre-clinical studies will be conducted prior to evaluating the desirability of commencement of clinical trials in humans for this compound. However, it is likely that any such clinical trials will commence later than the previously mentioned products in development based on assessment of medical need.

END

For more information, please contact:

Mr Neil Leggett CEO and Managing Director Agenix Limited Ph: 61 7 3370 6310

Agenix Limited [ASX: AGX, OTC (NASDAQ): AGXLY ] is a biotechnology company based in Brisbane, Australia. Through its wholly owned subsidiaries, Agen Biomedical Ltd and Agenix Biopharmaceutical (Shanghai), the company has a strategic goal of building and developing a pipeline of therapeutic and imaging products.

Agen Biomedical’s lead candidate is its high-technology blood clot-imaging agent, ThromboView[®] ,which has been undergoing human clinical trials in the United States, Canada and Australia. ThromboView[®] uses radio-labelled antibodies to locate blood clots in the body, and could revolutionise the global clot diagnostic imaging market. Preparation is underway for commencement of a Phase II pulmonary embolism clinical trial in the United States and Canada. ThromboView[®] is being developed with the assistance of the Australian Federal Government through its START scheme. ThromboView[®] is a registered trademark of Agen Biomedical Ltd.

Agenix Biopharmaceutical (Shanghai) owns two associated Chinese life sciences companies. One, Shanghai Rui Guang Bio-Pharma Development Co., Ltd, is a biopharmaceutical company which has a pipeline of anti-viral drugs in development. Its lead product candidate, a hepatitis B virus drug, has successfully completed Phase III clinical trials in China and is awaiting China State Food and Drug Administration approval for market launch in China. The second, Shanghai Yi Sheng Yuan Pharmaceutical Co., Ltd, has a GMP certified manufacturing facility which has the capacity to produce 150 million tablets per annum (based on a 5-day working week at 8 hours per day).

www.agenix.com